Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 and Serplulimab as Neoadjuvant Therapy in NSCLC
NCT07269782Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in non-small cell lung cancer (NSCLC), sponsored by Henlius. Started Jan 2026; status: recruiting.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07269782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269782.